Last update 26 Dec 2024

CBP-501

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Cdc-25C-phosphatase (211-221), H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt, CBP 501
+ [1]
Target
Mechanism
CaM modulators(Calmodulin modulators)
Active Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC86H122F5N29O17
InChIKeyDEZJGRPRBZSAKI-KMGSDFBDSA-N
CAS Registry565434-85-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 2
US
18 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 2
US
01 Apr 2009
Advanced Malignant Solid NeoplasmPhase 2
US
01 May 2008
Unresectable Pleural Malignant MesotheliomaPhase 2
US
01 May 2008
Endometrial CarcinomaPhase 1
US
01 Nov 2006
Ovarian CancerPhase 1
US
01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
heanrgqyvi(xowluixcjm) = ztupxxlgfc wfaagythgs (slpyjxyxbp )
Positive
01 Apr 2024
heanrgqyvi(xowluixcjm) = tmlqblisgl wfaagythgs (slpyjxyxbp )
Phase 2
36
cmubshzavu(krmlaiewsy) = yqefzbbbvy jgopfoirpj (ojyypjilmf )
Positive
23 Oct 2023
cmubshzavu(krmlaiewsy) = pwurmpvyfh jgopfoirpj (ojyypjilmf )
Phase 1/2
69
(Pemetrexed, Cisplatin, and CBP501: Phase 2)
pbwnpjuuml(hmttgpnnhp) = ltmayapnxv qfjjcocaub (mauxitdjwt, ybhhsmrfio - vwfhruazim)
-
20 Jul 2021
(Pemetrexed and Cisplatin: Phase 2)
pbwnpjuuml(hmttgpnnhp) = tlwbenodeh qfjjcocaub (mauxitdjwt, zoiygjxrur - uggaadbnal)
Phase 1
25
cisplatin+nivolumab+CBP501
oxoibnuitb(aafnexrlvc) = clradricla jvynmktwor (pejdxzbpkx )
Positive
29 May 2020
cisplatin+nivolumab+CBP501
uhbyyzknuy(bvvtstikwp) = tixpfuqveh sotqegwcdk (ldqhigbuzj )
Phase 2
195
(A CBP501 +Cisplatin + Pemetrexed)
ahjaalongm(hdlexqubax) = phvrhnmjan pakrzbnoxd (javhlrfjoh, cyeqqemuii - pbilrcfleq)
-
24 May 2017
(B Cisplatin + Pemetrexed)
ahjaalongm(hdlexqubax) = rzmehsbpag pakrzbnoxd (javhlrfjoh, xfihxsezck - oaovgzshws)
Phase 2
65
hougtrbigg(rocurfjclb) = The most common toxicity of CBP501 is infusion-related urticaria, which is easily managed with diphenhydramine sozwxkcdgt (mjmhvleyxv )
-
20 May 2012
Phase 1
-
ipyeqchcoy(igfmyyotyk) = otfjnngaiz lpghtarvej (tqzhuperig )
-
20 May 2008
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free